|
NOTE 3 — REVENUES
Revenues disaggregated by category were as follows (in thousands):
|
|
|
Three Months Ended September 30, 2019
|
|
|
Nine Months Ended September 30,
|
|
|
|
|
2019
|
|
|
2018
|
|
|
2019
|
|
|
2018
|
|
|
Endari®
|
|
$
|
5,994
|
|
|
$
|
4,803
|
|
|
$
|
16,960
|
|
|
$
|
7,863
|
|
|
Other
|
|
|
90
|
|
|
$
|
79
|
|
|
|
300
|
|
|
|
372
|
|
|
Revenues, net
|
|
|
6,084
|
|
|
|
4,882
|
|
|
|
17,260
|
|
|
|
8,235
|
|
The following table summarizes the revenue allowance and accrual activities for the nine months ended September 30, 2019 (in thousands):
|
|
|
Trade Discounts, Allowances and Chargebacks
|
|
|
Government Rebates and Other Incentives
|
|
|
Returns
|
|
|
Total
|
|
|
Balance as of December 31, 2018
|
|
$
|
303
|
|
|
$
|
1,880
|
|
|
$
|
181
|
|
|
$
|
2,364
|
|
|
Provision related to sales in the current year
|
|
|
1,039
|
|
|
|
2,368
|
|
|
|
190
|
|
|
|
3,597
|
|
|
Adjustments related prior period sales
|
|
|
(218
|
)
|
|
|
(1,082
|
)
|
|
|
—
|
|
|
|
(1,300
|
)
|
|
Credit and payments made
|
|
|
(866
|
)
|
|
|
(1,816
|
)
|
|
|
—
|
|
|
|
(2,682
|
)
|
|
Balance as of September 30, 2019
|
|
$
|
258
|
|
|
$
|
1,350
|
|
|
$
|
371
|
|
|
$
|
1,979
|
|
The following table summarizes revenues attributable to each of our customers who accounted for 10% or more of our total revenues (as a percentage of total revenues):
|
|
|
Three Months Ended September 30, 2019
|
|
|
Nine Months Ended September 30,
|
|
|
|
|
2019
|
|
|
2018
|
|
|
2019
|
|
|
2018
|
|
|
AmerisourceBergen Specialty Group
|
|
|
62
|
%
|
|
|
90
|
%
|
|
|
60
|
%
|
|
|
88
|
%
|
|
McKesson Plasma and Biologics LLC
|
|
|
22
|
%
|
|
|
4
|
%
|
|
|
21
|
%
|
|
|
3
|
%
|
|